Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;101(2):140-159.
doi: 10.1111/aos.15263. Epub 2022 Sep 30.

Comparative efficacy of treatments for chronic central serous chorioretinopathy: A systematic review with network meta-analyses

Elon H C van Dijk  1   2 , Helena M A Feenstra  1 , Jakob Bjerager  3 , Jakob Grauslund  4   5   6 , Camiel J F Boon  1   7 , Yousif Subhi  3   4
Affiliations
Free article

Comparative efficacy of treatments for chronic central serous chorioretinopathy: A systematic review with network meta-analyses

Elon H C van Dijk et al. Acta Ophthalmol. 2023 Mar.
Free article

Abstract

Treatment of chronic central serous chorioretinopathy (cCSC) remains a topic of controversy. As cCSC is a disease that can wax and wane, treatment efficacy is difficult to assess especially when trials compare active treatments without any placebo/control group. In this study, we systematically reviewed short-term efficacies of any cCSC treatment tested in randomized controlled trials (RCT) and employed network meta-analyses to compare to non-treatment controls. We searched 11 literature databases on 20 March 2022 for RCTs of treatment of cCSC. We identified 17 RCTs including a total of 1172 eyes. Treatments included conventional laser (44 eyes), half-dose or half-fluence photodynamic therapy (PDT) (298 eyes), ranibizumab (16 eyes), antioxidants (50 eyes), mineralocorticoid receptor antagonists (187 eyes), rifampicin (91 eyes), selective retina therapy (SRT) (67 eyes) and subthreshold micropulse laser (192 eyes). Compared with controls, significant benefit on complete subretinal fluid resolution was only obtained from half-dose or half-fluence PDT (OR: 20.6; 95% CI: 6.3-66.7; p < 0.0001) and conventional laser (OR: 36.4; 95% CI: 2.0-655.7; p = 0.015), and at an order of magnitude lower degree from SRT (OR: 3.4; 95% CI: 1.7-6.8; p = 0.00075). Compared with controls and after sensitivity analyses, significant benefit in the change in best-corrected visual acuity was only obtained by half-dose/-fluence PDT (-0.13 logMAR; 95% CI: -0.20 to -0.06 logMAR; p = 0.00021). In conclusion, three treatment options provide significant improvement over no treatment: half-dose/-fluence PDT, conventional laser and to a much lesser degree SRT. Considering that conventional laser can only be applied for extrafoveal leaks, and the long-term data available for PDT-based treatments finding persisting treatment results, half-dose or half-fluence PDT is the only viable treatment option for patients with cCSC. Shortage issues with verteporfin should not lead to employment of ineffective treatment modalities, as they put patients at unnecessary risk of adverse events.

Keywords: central serous chorioretinopathy; network meta-analysis; subretinal fluid; systematic review; treatment comparison.

PubMed Disclaimer

References

REFERENCES

    1. Bae, S.H., Heo, J., Kim, C., Kim, T.W., Shin, J.Y., Lee, J.Y. et al. (2014) Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial. Ophthalmology, 121, 558-565.
    1. Bicket, A.K., Le, J.T., Azuara-Blanco, A., Gazzard, G., Wormald, R., Bunce, C. et al. (2021) Minimally invasive glaucoma surgical techniques for open-angle glaucoma: an overview of Cochrane systematic reviews and network meta-analysis. JAMA Ophthalmology, 139, 983-989.
    1. Bousquet, E., Beydoun, T., Rothschild, P.R., Bergin, C., Zhao, M., Batista, R. et al. (2015) Spironolactone for NONRESOLVING central serous chorioretinopathy: a randomized controlled crossover study. Retina, 35, 2505-2515.
    1. Breukink, M.B., Dingemans, A.J., den Hollander, A.I., Keunen, J.E., MacLaren, R.E., Fauser, S. et al. (2016) Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life. Clinical Ophthalmology, 11, 39-46.
    1. Brinks, J., van Dijk, E.H.C., Meijer, O.C., Schlingemann, R.O. & Boon, C.J.F. (2022) Choroidal arteriovenous anastomoses: a hypothesis for the pathogenesis of central serous chorioretinopathy and other pachychoroid disease spectrum abnormalities. Acta Ophthalmologica. [ePub ahead of print]. Available from: https://doi.org/10.1111/aos.15112

Publication types

MeSH terms

LinkOut - more resources